Hydroxyzine Hydrochloride

Neurotic Disorders, Generalized Anxiety Disorder, Itching + 5 more

Treatment

13 FDA approvals

20 Active Studies for Hydroxyzine Hydrochloride

What is Hydroxyzine Hydrochloride

Hydroxyzine

The Generic name of this drug

Treatment Summary

Hydroxyzine is a medication used to treat allergic reactions, reduce itching, and relieve anxiety. It was developed in 1955 and is still commonly used today. Its active ingredient, cetirizine, is found in many medications used for allergies. Hydroxyzine is also used to treat generalized anxiety disorder and tension caused by psychoneurosis.

Vistaril

is the brand name

Hydroxyzine Hydrochloride Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vistaril

Hydroxyzine

1957

585

Approved as Treatment by the FDA

Hydroxyzine, also known as Vistaril, is approved by the FDA for 13 uses which include Nausea and Generalized Anxiety Disorder .

Nausea

Generalized Anxiety Disorder

Neurotic Disorders

Nausea and vomiting

Nausea and Vomiting of Pregnancy

Pruritus

Allergic Conditions

Surgical and medical procedures

Nausea

Itching

Hypersensitivity

Neurotic Disorders

histamine

Effectiveness

How Hydroxyzine Hydrochloride Affects Patients

Hydroxyzine is used to reduce itching and other allergic symptoms, and can also be used as a sedative to reduce anxiety. It starts to take effect between 15 and 60 minutes after taking it and its effects last for up to 6 hours. If you take hydroxyzine and have a procedure requiring general anaesthetic, you should lower any other CNS depressants you are taking to avoid a potential overdose. Hydroxyzine may also cause a dangerous heart rhythm issue, which means it should be used with extra caution in people who are at risk of this.

How Hydroxyzine Hydrochloride works in the body

Hydroxyzine works by blocking the activity of histamine H<sub>1</sub> receptors, which are responsible for allergic reactions. This helps relieve symptoms like itching, runny nose, and watery eyes. It also has sedative properties that help with anxiety. Additionally, it may have antiemetic effects, which means it can help prevent vomiting.

When to interrupt dosage

The proposed dosage of Hydroxyzine Hydrochloride is contingent upon the diagnosed affliction, including Allergic Conditions, Neurotic Disorders and Nausea. The measure also relies upon the method of delivery listed in the table beneath.

Condition

Dosage

Administration

Generalized Anxiety Disorder

, 50.0 mg/mL, 10.0 mg/mL, 25.0 mg, 10.0 mg, 50.0 mg, 25.0 mg/mL, 100.0 mg, 5.0 mg/mL

, Intramuscular, Solution, Solution - Intramuscular, Oral, Syrup, Syrup - Oral, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Injection, solution, Liquid, Liquid - Intramuscular, Suspension - Oral, Suspension, Solution - Oral, Sublingual, Troche, Troche - Sublingual

Itching

, 50.0 mg/mL, 10.0 mg/mL, 25.0 mg, 10.0 mg, 50.0 mg, 25.0 mg/mL, 100.0 mg, 5.0 mg/mL

, Intramuscular, Solution, Solution - Intramuscular, Oral, Syrup, Syrup - Oral, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Injection, solution, Liquid, Liquid - Intramuscular, Suspension - Oral, Suspension, Solution - Oral, Sublingual, Troche, Troche - Sublingual

Surgical and medical procedures

, 50.0 mg/mL, 10.0 mg/mL, 25.0 mg, 10.0 mg, 50.0 mg, 25.0 mg/mL, 100.0 mg, 5.0 mg/mL

, Intramuscular, Solution, Solution - Intramuscular, Oral, Syrup, Syrup - Oral, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Injection, solution, Liquid, Liquid - Intramuscular, Suspension - Oral, Suspension, Solution - Oral, Sublingual, Troche, Troche - Sublingual

Nausea

, 50.0 mg/mL, 10.0 mg/mL, 25.0 mg, 10.0 mg, 50.0 mg, 25.0 mg/mL, 100.0 mg, 5.0 mg/mL

, Intramuscular, Solution, Solution - Intramuscular, Oral, Syrup, Syrup - Oral, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Injection, solution, Liquid, Liquid - Intramuscular, Suspension - Oral, Suspension, Solution - Oral, Sublingual, Troche, Troche - Sublingual

Nausea

, 50.0 mg/mL, 10.0 mg/mL, 25.0 mg, 10.0 mg, 50.0 mg, 25.0 mg/mL, 100.0 mg, 5.0 mg/mL

, Intramuscular, Solution, Solution - Intramuscular, Oral, Syrup, Syrup - Oral, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Injection, solution, Liquid, Liquid - Intramuscular, Suspension - Oral, Suspension, Solution - Oral, Sublingual, Troche, Troche - Sublingual

Hypersensitivity

, 50.0 mg/mL, 10.0 mg/mL, 25.0 mg, 10.0 mg, 50.0 mg, 25.0 mg/mL, 100.0 mg, 5.0 mg/mL

, Intramuscular, Solution, Solution - Intramuscular, Oral, Syrup, Syrup - Oral, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Injection, solution, Liquid, Liquid - Intramuscular, Suspension - Oral, Suspension, Solution - Oral, Sublingual, Troche, Troche - Sublingual

Neurotic Disorders

, 50.0 mg/mL, 10.0 mg/mL, 25.0 mg, 10.0 mg, 50.0 mg, 25.0 mg/mL, 100.0 mg, 5.0 mg/mL

, Intramuscular, Solution, Solution - Intramuscular, Oral, Syrup, Syrup - Oral, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Injection, solution, Liquid, Liquid - Intramuscular, Suspension - Oral, Suspension, Solution - Oral, Sublingual, Troche, Troche - Sublingual

histamine

, 50.0 mg/mL, 10.0 mg/mL, 25.0 mg, 10.0 mg, 50.0 mg, 25.0 mg/mL, 100.0 mg, 5.0 mg/mL

, Intramuscular, Solution, Solution - Intramuscular, Oral, Syrup, Syrup - Oral, Tablet, film coated - Oral, Tablet, film coated, Capsule - Oral, Capsule, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Injection, solution, Liquid, Liquid - Intramuscular, Suspension - Oral, Suspension, Solution - Oral, Sublingual, Troche, Troche - Sublingual

Warnings

Hydroxyzine Hydrochloride has thirteen contraindications, thus it should not be blended with the conditions stated in the following table.

Hydroxyzine Hydrochloride Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Hydroxyzine may interact with Pulse Frequency

Cardiac Arrhythmia

Do Not Combine

Pulse Frequency

Do Not Combine

Pregnancy Trimester, First

Do Not Combine

Sudden Cardiac Death

Do Not Combine

Porphyrias

Do Not Combine

Long QT Syndrome

Do Not Combine

Asthma

Do Not Combine

Bradycardia

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Electrolyte imbalance

Do Not Combine

Torsades de Pointes

Do Not Combine

There are 20 known major drug interactions with Hydroxyzine Hydrochloride.

Common Hydroxyzine Hydrochloride Drug Interactions

Drug Name

Risk Level

Description

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Hydroxyzine.

Azelastine

Major

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Hydroxyzine.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Hydroxyzine.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Hydroxyzine.

Hydroxyzine Hydrochloride Toxicity & Overdose Risk

The toxic dose of hydroxyzine for rats is 840mg/kg and 400mg/kg for mice. Symptoms of overdose include drowsiness, seizures, stupor, nausea, and vomiting. Treatments for overdose may include inducing vomiting and using a stomach rinse. Other treatments should focus on providing general support and controlling any low blood pressure. Caffeine and sodium benzoate injections may be used to counteract CNS depressant effects, but dialysis is unlikely to help.

Hydroxyzine Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Hydroxyzine Hydrochloride?

229 clinical trials are actively assessing the potential of Hydroxyzine Hydrochloride to ameliorate Generalized Anxiety Disorder, facilitate Surgical and medical procedures and reduce Itch.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

173 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

histamine

0 Actively Recruiting

Itching

3 Actively Recruiting

Phase 3, Not Applicable

Nausea

0 Actively Recruiting

Nausea

0 Actively Recruiting

Neurotic Disorders

0 Actively Recruiting

Surgical and medical procedures

0 Actively Recruiting

Hypersensitivity

0 Actively Recruiting

Patient Q&A Section about hydroxyzine hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is hydroxyzine hydrochloride used for?

"Hydroxyzine is a medication used to help with anxiety, tension, and nervousness. It can also be used as a sleep aid before surgery."

Answered by AI

What kind of drug is hydroxyzine hydrochloride?

"Hydroxyzine is an antihistamine medication that works by blocking the action of histamine in the body to relieve allergic symptoms, and by decreasing activity in the brain."

Answered by AI

Is hydroxyzine a sleeping pill?

"The main reason why Hydroxyzine (Atarax, Vistaril) is commonly prescribed is because it has sedative properties that can help people with sleep disorders like insomnia. Additionally, since it has calming effects, it is often used as an anaesthetic with other medications before surgery."

Answered by AI

Is hydroxyzine hydrochloride a Xanax?

"Hydroxyzine and Xanax are two different types of drugs. Hydroxyzine is an antihistamine that can make you dry and sleepy, while Xanax is a drug used to reduce anxiety. Vistaril is the brand name for hydroxyzine."

Answered by AI

Clinical Trials for Hydroxyzine Hydrochloride

Image of Northwestern University in Evanston, United States.

Sleep and Dreaming Practices for Anxiety

18+
All Sexes
Evanston, IL

People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking. Recent advances in sleep monitoring, dream communication, and lucid dream induction now make it possible to study these practices using scientific methods. This study is a randomized controlled trial designed to examine the feasibility and effects of a Dream-Yoga-inspired intervention compared with an active control condition. The intervention combines waking and dreaming practices that are adapted for individuals without prior experience and delivered using virtual reality-based training and home sleep technology. The program is designed to be scalable and culturally neutral, without requiring prior knowledge of contemplative or religious traditions. The primary goals of the study are to characterize sleep and waking neurophysiology associated with Dream-Yoga-inspired practices and to evaluate whether participation is associated with changes in sleep-related brain activity and cognitive processes. Outcomes include measures of lucid dreaming, sleep physiology, and waking cognitive and perceptual processes. Anxiety will be assessed as an exploratory outcome to examine whether participation may be associated with changes in emotional experience. This study is not designed to provide treatment for anxiety or other clinical conditions. Results from this study will help inform the development of scalable sleep-based mental training approaches and guide future research on the use of dreaming and sleep practices to support psychological health and well-being

Phase < 1
Waitlist Available

Northwestern University (+1 Sites)

Image of Liao Lab at UCSF in San Francisco, United States.

Audio-Based Therapy for Anxiety in Psoriasis

18+
All Sexes
San Francisco, CA

Anxiety in psoriasis is associated with impaired quality of life, and the prevalence of anxiety symptoms in psoriatic populations is approximately 34% and anxiety disorders up to 16%. Many experts recommend routine screening, referral, and interventions for anxiety in psoriasis; however, many barriers inhibit access to mental health resources and proper management. To our knowledge, there is a lack of easily accessible interventions that manage anxiety. Audio-based therapy offers convenient and effective interventions that show reduced anxiety in published, randomized studies and is a promising management for psoriasis patients. This study will evaluate the effects of audio therapy in patients with psoriasis and measure changes in overall symptoms.

Waitlist Available
Behavior

Liao Lab at UCSF

Wilson Liao, MD

Have you considered Hydroxyzine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Hydroxyzine Hydrochloride, we think they might fit your search criteria.
Go to Trials

Have you considered Hydroxyzine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Hydroxyzine Hydrochloride, we think they might fit your search criteria.
Go to Trials
Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Have you considered Hydroxyzine Hydrochloride clinical trials?

We made a collection of clinical trials featuring Hydroxyzine Hydrochloride, we think they might fit your search criteria.
Go to Trials